Medicine moves through people. Intelligence should move with it.

A medicines decision can begin in a research paper, a pharmacy, a general practice or a hospital committee. Its value depends on what happens next.

In development · Intended scope and questions for evaluation

The organisation.
The people around it.

Released capacity, cost avoidance, cash savings, income and health outcomes are different effects. Keeping them separate makes the programme easier to challenge.

The people involved

Medicines optimisation, clinical services, operations, finance, procurement, digital and governance functions.

The dependencies

Programme sponsors, professional leads, service managers, finance, procurement, digital, information governance and evaluation colleagues.

What to examine

Evidence accuracy, clinical and local relevance, workload, resources, permissions, affordability and reasons to stop or revise.

Explore the ecosystem

An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.

The work behind every medicines decision.

Which evidence matters here? Who needs to review it? What would a change require from the people delivering care? These questions sit behind medicines decisions across the supply chain. Their answers shape whether an opportunity can become useful practice.

The scale is significant. NHSBSA reports 1.30 billion prescription items dispensed in the community in England in 2025/26. Each setting still has its own people, responsibilities and operating constraints. Our interest is in the work that connects a relevant evidence case with a decision that someone can carry forward.

Make the evidence easier to examine.

A useful evidence case gives a professional something they can interrogate: the source, its relevance, the assumptions behind the comparison and the questions still open. That matters to a pharmacist preparing a review, a formulary team comparing an option and a finance lead examining the proposed value.

Our research direction focuses on the quality and effort of that review. It asks how preparation can become more useful while keeping the reviewer able to challenge the reasoning. The full task includes finding, checking, correcting and explaining the evidence to the next person.

Different roles. A decision they can work on together.

A community owner needs a change that fits the team and makes commercial sense. A GP or primary-care pharmacist needs a clear account of the medicines work around a clinical decision. A hospital medicines team needs an implementation case that can withstand professional and organisational review.

For a pharmacy group, the challenge extends across branches. For a remote provider, it crosses prescribing, dispensing and delivery partners. Industry and supply teams may bring a different operational constraint. The opportunity is to identify a defined task and make its evidence, responsibilities and consequences easier to understand.

PHARMORIS | The Medicines Action Layer.

PHARMORIS brings our medicines intelligence ambition into one development programme. Its purpose is to connect the evidence case, the decision, the people accountable for implementation and the review of what followed.

This is a connected view of medicines work. The questions are practical: what is being proposed, why does it matter in this setting, who owns the next step and how will the intended value be examined? A focused evaluation gives those questions a concrete workflow and a fair comparison.

PHARMORIS received a £49,928 Innovate UK award for its generics optimisation development programme. We are grateful for support that helped create the opportunity to develop this work and pursue the evidence it needs.

Healthcare is local. The intelligence has to understand that.

In England, medicines optimisation involves provider teams, integrated care boards and regional leadership, with responsibilities that need to be understood in the local setting. A chief pharmacist, a medicines committee, a budget holder and a procurement team may each have a different part in the same decision.

In general practice, structured medication reviews place the person and shared decision-making at the centre of the clinical review. Our organisational focus concerns the preparation, coordination and follow-through around medicines work. Scotland, Wales and Northern Ireland have their own arrangements; the operating context must be established for each proposed use case.

A wider ambition, grounded in the system using it.

US health systems have their own formulary and Pharmacy and Therapeutics processes. Health plans, pharmacy benefit managers, community pharmacy owners and public programmes hold different responsibilities for access, coverage, payment and delivery. They should not be treated as interchangeable buyers.

Our international evaluation interest starts with a defined organisational task and the people who own it. Preparing formulary evidence, coordinating an agreed change and examining operational burden are possible questions to explore. The local evidence, purchasing route and governance requirements shape what a useful proposition would be.

AI that makes professional judgement easier to exercise.

Good medicines intelligence should help people see why an output deserves attention and when it needs to be challenged. Source context, uncertainty and the limits of a comparison are part of that experience. The interface has to support a thoughtful decision under the pressures of real work.

For a prospective healthcare use case, the intended purpose determines the evidence and assurance work required. We consider clinical safety, data protection, security, accessibility and the professional role alongside the workflow. NHS DTAC and NICE’s evidence framework inform that planning; the requirements must be assessed for the actual technology and setting.

Build evidence around the work people recognise.

Our planned evidence directions examine review quality and total effort, implementation follow-through, appropriate reliance on AI and the economics of adoption. A useful comparison includes the checking, training and support that a team actually has to provide.

This gives an evaluation partner a clearer starting point: one recurring task, an accountable team, a credible existing approach and a result that would change a decision. The development portfolio extends these questions across evidence review, implementation planning, supply resilience and value assurance.

Bring the medicines decision your team wants to move forward.

Whether you lead one pharmacy, a group, a clinical service or a health system, start with the task, the team and what a useful improvement would mean.

Sources and further reading

Bring the question
your organisation
needs to move.

Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.

Discuss a PHARMORIS evaluation

An initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.

One programme. A whole system of people.

Original NEUVIOR motion explainer · 36 seconds · no audio. The film illustrates intended scope and questions for evaluation. Read the transcript.